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Zinc transporter 8 (ZnT8), encoded by SLC30A8, is chiefly expressed within pancreatic islet cells,
where it mediates zinc (Zn2) uptake into secretory granules. Although a common nonsynony-
mous polymorphism (R325W), which lowers activity, is associated with increased type 2 diabetes
(T2D) risk, rare inactivating mutations in SLC30A8 have been reported to protect against T2D.
Here, we generate and characterize newmouse models to explore the impact on glucose homeo-
stasis of graded changes in ZnT8 activity in the -cell. Firstly, Slc30a8was deleted highly selectively
in these cells using the novel deleter strain, Ins1Cre. The resultant Ins1CreZnT8KO mice displayed
significant (P  .05) impairments in glucose tolerance at 10 weeks of age vs littermate controls,
and glucose-induced increases in circulating insulin were inhibited in vivo. Although insulin re-
lease from Ins1CreZnT8KO islets was normal, Zn2 release was severely impaired. Conversely,
transgenic ZnT8Tg mice, overexpressing the transporter inducibly in the adult -cell using an
insulin promoter-dependent Tet-On system, showed significant (P .01) improvements in glucose
tolerance compared with control animals. Glucose-induced insulin secretion from ZnT8Tg islets
was severely impaired, whereas Zn2 release was significantly enhanced. Our findings demon-
strate that glucose homeostasis in the mouse improves as -cell ZnT8 activity increases, and
remarkably, these changes track Zn2 rather than insulin release in vitro. Activation of ZnT8 in
-cells might therefore provide the basis of a novel approach to treating T2D. (Molecular
Endocrinology 30: 77–91, 2016)
The regulation of insulin secretion by glucose involvesthe uptake and metabolism of the sugar by pancreatic
-cells (1), stimulation of mitochondrial oxidative metab-
olism (2), Ca2 influx (3), and the exocytosis of the hor-
mone from dense core secretory granules (4, 5) where it is
stored in a near-crystalline form alongside Zn2 and
Ca2 ions (6). Although it is increasingly accepted that
impaired insulin secretion underlies the development of
type 2 diabetes (T2D) (7), a disease affecting more than
8% of the adult population worldwide (8), the mecha-
nisms involved remain poorly understood (9). Nonethe-
less, disease risk is strongly influenced by both genetic
(10) and environmental (11) factors.
A nonsynonymous variant in the SLC30A8 gene asso-
ciated with elevated T2D risk was identified by genome-
wide association studies (GWAS) in 2007 (12). Expressed
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almost exclusively in pancreatic - and -cells (13–15),
SLC30A8 encodes a secretory granule-resident zinc trans-
porter, zinc transporter 8 (ZnT8), implicated in the accu-
mulation of zinc within these organelles and thus in insu-
lin storage (16). Given these likely roles, SLC30A8/ZnT8
has been mooted as a potentially tractable new target for
personalized disease therapy.
Subsequent functional studies on the expressed ZnT8
protein (14, 17) demonstrated that the risk (R325) vari-
ant is a less active zinc transporter than the protective (W)
form. Consequently, possession of risk alleles seems likely
to impair insulin crystallization and storage. Supporting
this view, mice inactivated globally (14, 18) or selectively
in the -cell (15, 19) for Slc30a8 revealed striking abnor-
malities in the formation of dense cores within insulin
granules. Surprisingly, however, measurements of insulin
release from isolated islets from Slc30a8 null mice re-
vealed either no change (18) or improved (14, 19) glu-
cose-stimulated insulin secretion from isolated islets or
the perfused pancreas, and unchanged insulin content.
Despite this, glucose homeostasis and circulating insulin
levels were both lowered in ZnT8 null animals. Providing
a possible explanation for this conundrum, Tamaki et al
(19) demonstrated that the enhanced release of Zn2 ions
alongside insulin in W-variant carriers suppresses insulin
clearance (and presumably nonproductive insulin signal-
ing) by the liver, favoring insulin action on this, as well as
other tissues (notably, adipocytes and skeletal muscle).
An observed increase in C-peptide to insulin ratio in hu-
man R-carriers supported this model, because the mature
hormone, but not proinsulin, is expected to be cleared by
the liver. Moreover, Slc30a8 elimination from the mouse
has no effect on insulin processing (14, 18), arguing
against a -cell-autonomous action of the variant on the
release of mature vs partially processed forms. Together,
the above findings have stimulated the search for activa-
tors of the transporter which, by favoring Zn2 accumu-
lation by -cell secretory granules, may eventually prove
useful in the clinic.
However, and challenging the above view, a recent
study based largely on Swedish, Finnish, and otherNorth-
ern European populations, but also including individuals
from elsewhere, identified rare (0.1% of the popula-
tion) nonsense (truncating) or missense mutations in the
SLC30A8 gene. Unexpectedly, the carrier population
showed an approximately 3-fold enrichment for healthy
individuals vs those with T2D, implying a protective role
for themutant transporter. Although only a small number
of carriers was involved (345 in total of 150 000 sub-
jects sequenced) a range of structurally distinct variants
was found in cohorts with differing ancestry, providing
evidence that the SLC30A8 mutations, rather than other
polymorphisms in the same linkage disequilibrium block,
were likely to explain the changes in disease risk.
The above findings are nonetheless difficult to recon-
cile with the observed increase in T2D risk in carriers of
the common risk alleles. Although an activating effect of
the identified mutants on the remaining allele cannot be
excluded absolutely, an alternative explanation (20) is
that a complex interplay between insulin storage and
Zn2 release by -cells, and downstream effects on target
tissues including the liver, results in a bimodal (bell-
shaped) dependence of T2D risk on ZnT8 activity. Thus,
modest decreases in -cell ZnT8 activity, as observed in
carriers of the common risk (R) variants, may act chiefly
by lowering -cell Zn2 secretion, thus enhancing insulin
clearance by the liver. On the other hand, a more substan-
tial lowering of ZnT8 activity, engendered by rare loss-
of-function alleles, may lead to a more dramatic increase
in insulin release from the pancreas, an effect outweighing
impaired Zn2 release and altered insulin clearance.
The impact of deleting ZnT8 from the -cell in mice
has also been the subject of some debate. Thus, one recent
study (21) reported that global knockout on a pure
C57BL6 background exerted no effects on glucose toler-
ance, in contrast to findings on more mixed backgrounds
(14, 18). Moreover, several previously reported -cell-
selective deletion models are complicated by deletion in
other tissues, including the brain, whenCre deleter strains
(notably, RIP2Cre and Pdx1), with activity in these tis-
sues (22), are used. Correspondingly, RIP2Cre:ZnT8
mice gain more weight vs controls on a high fat diet than
observed with globally deleted animals (23). The latter
findings argue for a role for ZnT8 in a small number of
neuronal cells in which the Pdx1 or Ins2 promotermay be
at least transiently active during development or at later
stages. On the other hand, the mouse insulin promoter 1
Cre (MIPCre) used in Ref. 19 may also be affected by the
coexpression of GH encoded by the cDNA included in
this transgene (24).
Our first goal here was therefore to explore the impact
of deleting ZnT8 more specifically in the -cell, and on a
pure C57BL6 background, using a new deleter strain in
which the Ins1 promoter, which is inactive in brain and
other tissues (22), drives expression of Cre after introduc-
tion into the endogenous locus (“knock-in”) (25, 26).
Importantly, Ins1Cre mice do not express the GH mini-
gene, unlike both RIP2Cre (24) and MIPCre mice (27),
and mice bearing the transgene alone display no abnor-
malities in glucose tolerance (22) (Rutter, G.A., unpub-
lished results).
Up to now, there have been no attempts to examine
the effect of overexpressing ZnT8 selectively in the
-cell, thus mimicking one of the likely actions of
78 Mitchell et al Impact of ZnT8 Modulation on Glucose Homeostasis Mol Endocrinol, January 2016, 30(1):77–91
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 11 January 2016. at 08:52 For personal use only. No other uses without permission. . All rights reserved.
agents capable of stimulating the activity of the trans-
porter. Our second goal here was therefore to generate
a series of transgenic mouse lines in which ZnT8 ex-
pression is under the control of rat insulin promoter
Tet-On system (28).
We demonstrate that highly selective deletion of ZnT8
in the -cell leads to dense core granule misformation and
glucose intolerance. By contrast, overexpression of the
transporter in the -cell in adults leads to improved glu-
cose tolerance but reduced insulin secretion, whereas
Zn2 release is markedly enhanced. A positive relation-
ship thus pertains between -cell ZnT8 expression (and
Zn2 secretion), and glucose tolerance. If reflective of
human physiology, these results lend weight to the view
that ZnT8 activation might prove beneficial in the con-
text of T2D.
Results
Impaired glucose tolerance and
insulin secretion in
Ins1Cre:ZnT8fl/fl mice
-Cell-selective deletion of ZnT8
with a variety of Cre deleter strains
(eg, RIP2 [15] andMIP [19]) display
varying degrees of recombination at
extrapancreatic sites, due to ectopic
expression of Cre. By contrast,
Ins1Cre knockin mice display no de-
tectable expression of the recombi-
nase in the brain, only very minor
recombination in other islet cells
(3% of -cells in utero), but more
than 94% recombination in -cells
(25, 29). We therefore used this
model to inactivate ZnT8 selectively
in -cells (Figure 1A). Confirming
efficient deletion of the endogenous
ZnT8 alleles in the -cell with
Ins1Cre, islets from Ins1Cre/:
ZnT8fl/fl (Cre) mice showed more
than 80% reduction in ZnT8
mRNA levels (**, P .01; two-way
ANOVA; Cre vs Cre; n  3 and
4, respectively) compared with litter
mate controls (Ins1 Cre/:ZnT8fl/
fl; Cre), with no changes in the ex-
pression of other ZnT family mem-
bers (Figure 1B). Loss of ZnT8
immunoreactivity was seen specifi-
cally in the -cell, and not the -cell,
compartment, as demonstrated us-
ing immunohistochemical analysis
of isolated islets, staining for insulin
and glucagon, respectively (Figure
1C), and counting the number of
ZnT8 positive cells colocalized with
insulin and glucagon (Figure 1D). A
decrease in overall immunoreactiv-
Figure 1. Ins1Cre-mediated deletion of ZnT8 in pancreatic -cells. Mice carrying a LoxP site
together with a flippase recognition target-flanked neomycin selection cassette within intron 1,
and a single distal LoxP site within the upstream exon 1 containing the translational start codon,
were bred with the Ins1Cre deleter strain, leading to the removal of exon 1 of Slc30A8/ZnT8 (A).
Ins1Cre-mediated deletion of ZnT8 resulted in an approximate 80%–90% reduction in Slc30a8
expression (B) (**, P  .001 vs 3 Cre, 4 Cre), with no significant changes in the expression of
other ZnT family members (P  .05 by two-way ANOVA). Gene expression was normalized to
-actin, and fold change gene expression was determined using 2CT. B, ZnT8 protein
expression is reduced in islets from Cre animals, as shown by immunofluorescence staining,
which demonstrates deletion specifically in -cells (n  90) but not -cells (n  24) (C and D).
Deletion of ZnT8 revealed by Western (immuno)blotting of isolated islets from Ins1Cre/:ZnT8fl/
fl mice and controls (E). Values represent mean 	 SEM. Scale bar in C, 12.5 m.
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ity of more than 90% for monomeric ZnT8 was shown
using Western (immuno)blotting analysis (Figure 1E) com-
patible with an islet composition of approximately 70%–
80% -cells (30) and levels of ZnT8 expression in -cells
about 50% of those in -cells (Figure 1C and Ref. 14) .
Maintained on a regular chow diet, male Ins1Cre/:
ZnT8fl/fl mice displayed normal glucose tolerance at 6
weeks of age (not significant [ns]; repeated measures two-
way ANOVA; n 8 Cre and n 14 Cre, respectively)
(Figure 2A) but impaired responses to the sugar by 10
weeks (11.5 	 0.59 vs 13.6 	 0.74
mmol/L; Cre vs Cre; P .05; 30-
min time point; repeated measures
two-way ANOVA; n  8 and 11,
respectively) (Figure 2B). These
changes gradually resolved with age
(ns; repeated measures two-way
ANOVA; n  7 Cre and n  10
Cre) (Figure 2C). Female knockout
(KO) mice showed no evident ab-
normalities at either age (Supple-
mental Figure 1, A–F). Ins1Cre/:
ZnT8fl/fl (aged 10 wk) showed
significantly higher glucose re-
sponses (P  .001 15- and 30-min
time point, repeated measures two-
way ANOVA, n  9 Cre and n 
12 Cre) (Figure 2D) but lower in-
sulin responses (0.70 	 0.073 vs
0.49 	 0.072; Cre vs Cre; P 
.05; 30-min time point; repeated
measures two-way ANOVA; n 14
Cre and n  13 Cre) (Figure 2E)
in response to a 3-g/kg bodyweight
glucose injection, consistent with
impaired insulin secretion or en-
hanced clearance of the hormone.
Insulin sensitivitymeasured using an
insulin tolerance test was unchanged
in both male (Figure 2F) and female
(Supplemental Figure 2) Ins1Cre/
:ZnT8fl/fl mice, as assessed at 10 or
8weeks, respectively. These findings
are in line with those in global (14)
or mouse insulin 1 promoter-deleted
animals (19).
Unchanged glucose-, incretin-,
and KCl-stimulated insulin
secretion but altered Zn2
dynamics in isolated Ins1Cre/:
ZnT8fl/fl islets
Islets isolated from 10-week-old
male Ins1Cre/:ZnT8fl/fl mice
showed no change with respect to
control islets in in vitro insulin secre-
tion in response to 16.7 mmol/L glu-
Figure 2. In vivo assessment of glucose homeostasis in Ins1CreZnT8KO mice. Intraperitoneal
glucose tolerance test (IPGTT) and AUC of 6-week-old (A), 10-week-old (*, P .05, 30-min time
point) (B), and 14-week-old (C) male Ins1Cre/ZnT8fl/fl (Cre) and littermate control (Ins1CreZnT8/
ZnT8fl/fl, Cre) mice. Animals were injected with 1-g/kg bodyweight glucose and blood glucose
measured at time point 0, 15, 30, 60, 90, and 120 minutes after glucose injection (n 7–14
animals). Glucose (*** P .01, 15-min time point; ****, P .001, 30-min time point) (D) and
insulin (*, P .05, 30-min time point) (E) responses of 10-week-old male Ins1CreZnT8 mice after 3-g/
kg bodyweight glucose injection (n 13–14 animals per genotype). F, Insulin tolerance test of 10-
week-old Ins1CreZnT8 and littermate control male mice. Animals were injected with 0.75-U/kg
bodyweight insulin and blood glucose measured as per IPGTT. Numbers in solid bars in the
histograms indicate the number of animals studied. Values are mean	 SEM.
80 Mitchell et al Impact of ZnT8 Modulation on Glucose Homeostasis Mol Endocrinol, January 2016, 30(1):77–91
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 11 January 2016. at 08:52 For personal use only. No other uses without permission. . All rights reserved.
cose, incretin or depolarization induced with KCl (ns;
two-way ANOVA; n  12–16 replicates per genotype)
(Figure 3A). Secretion in response to lower (8 mmol/L)
glucose concentrations was also unchanged (Supplemen-
tal Figure 3A) and, similarly, glucose-stimulated insulin
release was not different between null and wild-type islets
assayed during perifusion at 16.7 mmol/L glucose (Sup-
plemental Figure 3B). Likewise, deletion of ZnT8 did not
affect the amplitude (0.50	 0.05 vs 0.47	 0.06; Cre vs
Cre; ns; Student’s t test; n 17 and 9 islets, respectively)
or area under the curve (AUC) (1132 	 19.7 vs 1107 	
24.2; Cre vs Cre; ns; Student’s t test; n  17 and 9
islets, respectively) of glucose (Figure 3B) or KCl-stimu-
lated intracellular free Ca2 ([Ca2]i) increases (ampli-
tude, 1.38 	 0.11 vs 1.23 	 0.15; AUC, 443 	 9.71 vs
450	 17.;3 Cre vs Cre; ns; Student’s t test; n 5 and
n  13 islets, respectively) (Figure
3C). Finally, -cell--cell connectiv-
ity (31), known to contribute to the
regulation of insulin release from in-
tact islets, was unaltered in ZnT8
null islets (Figure 3, D and E).
We next used the recombinant
Förster resonance energy transfer
(FRET)-based probe eCALWY4
(32, 33) to measure cytosolic Zn2
concentrations. Consistent with
findings in global ZnT8 null mice
(34), Ins1Cre/:ZnT8f/lfl -cells
showed a significant reduction in
free cytosolic Zn2 concentration
(920 0.3 	 261pM vs 212.8 	
32.5pM; **, P .01, Cre vs Cre,
Student’s t test, n 20 and 11 islets,
respectively) (Figure 4, A–C). Fur-
thermore, use of the cell surface-tar-
geted Zn2 binding probe zinc indi-
cator for monitoring induced
exocytotic release (ZIMIR) (35), to
measure Zn2 cosecreted from insu-
lin granules, demonstrated that
Ins1Cre/:ZnT8fl/fl islets secreted
substantially less Zn2 compared
with control islets after stimulation
with glucose (Figure 4D).
Ins1Cre/:ZnT8f/f mice show
altered insulin granule
morphology but preserved -
cell mass
The above metabolic and cellular
disturbances were accompanied by a
drastic change in secretory granule
morphology (Figure 5A), with a
near-complete loss of dense core
granules in islets from Ins1Cre/:
ZnT8fl/fl mice, and the emergence of
“atypical” granules possessing ab-
normal “rod-like” (0.65 	 0.28%
vs 31.9	 3.42%, Cre vs Cre, P
Figure 3. In vitro assessment of islets isolated from Ins1CreZnT8KO mice. Insulin secretion from
5 size-matched islets was assessed using a Homogenous Time-Resolved Fluorescence-based assay
(Materials and Methods). Briefly, islets were pretreated at 3mM glucose for 1 hour at 37°C
before being exposed to either 3mM glucose (G3), 16.7mM glucose (G16.7), 16.7mM glucose
plus 20nM GLP-1 (GLP-1), or 3mM glucose  30mM KCl (KCl) for 30 minutes at 37°C. Secreted
insulin was determined and, after normalization to total insulin, expressed as fold change vs the
3mM glucose condition (A). [Ca2]i dynamics were assessed using Nipkow spinning disk
microscopy. No significant differences were seen in either the amplitude or the AUC of glucose-
evoked (17mM; G17) whole-islet Ca2 rises (ns vs Cre; Student’s t test) (B). The number of
glucose-responsive cells was unchanged between Cre and Cre mice (data not shown).
Likewise, there were no differences seen in KCl-induced (30mM KCl) [Ca2]i rises (ns vs Cre
;
Student’s t test) (C). Correlation analyses of glucose-evoked Ca2 traces (32) showed no
difference in -cell--cell connectivity in Cre islets vs Cre islets at both low (3mM) and high
(11mM) glucose, indicating maintained cell quiescence and synchronicity, respectively. D,
Connectivity map depicting location, number, and strength (color coded; 0 [blue]  lowest, 1
[red]  highest) of significantly correlated cell pairs (E). Values represent mean 	 SEM.
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.0001, n  8 -cells/genotype) or “empty” (36.3 	
2.48% vs 85.6 	 1.37%, Cre vs Cre, P  .0001, n 
8 -cells/genotype) cores (Figure 5B). The total number of
granules was unchanged (129 	
9.25 vs 128 	 11.9; Cre vs Cre;
ns; Student’s t test; n  8 -cells/
genotype) (Figure 5C), but average
granule diameter was increased
(377.47 	 5.12 vs 328.09 	 5.46
nm, Cre vs Cre, P  .001, n 
204/226 granules) (Figure 5D),
likely reflecting increased osmotic
stress resulting from free electrolytes
in the ZnT8 null granule (18). Stain-
ing pancreatic slices for insulin and
glucagon (Figure 5E) showed no
changes in total -cell mass
(0.513	 0.07% vs 0.334	 0.17%;
Cre vs Cre; ns; Student’s t test;
n 3 animals per genotype) (Figure
5F), -cell mass (0.055	 0.015%vs
0.051 	 0.019%; Cre vs Cre; ns;
Student’s t test; n  3 animals per
genotype) (Figure 5G) or - to -cell
ratio (0.151 	 0.011 vs 0.206 	
0.025; Cre vs Cre; ns; Student’s t
test; n  3 animals per genotype)
(Figure 5H). These data are in line
with previous findings using alterna-
tive deleter strains to eliminate
ZnT8 from the -cell (14, 18, 36).
The above studies thus demon-
strate that deleting ZnT8 selectively
in the -cell leads to normal insulin,
but abnormal Zn2 secretion, in
vitro, but markedly lower post-
stimulation insulin levels and glu-
cose tolerance in vivo.
Improved glucose tolerance in
ZnT8 transgenic mice
To explore the impact of increas-
ing ZnT8 activity in -cells we next
generated transgenic mice in which
the expression of the transporter
was under the control of a bidirec-
tional tetracycline-inducible pro-
moter (37). -Cell-selective induc-
tion was then achieved by activation
of a Tet-On transactivator ex-
pressed selectively in -cells under
the control of the rat insulin 2 pro-
moter (RIP7-rtTA) (Figure 6A). Al-
though 7 founders were produced, we selected 2 (31 and
23; copy numbers 5 and 13, respectively) for further anal-
Figure 4. Intracellular zinc dynamics and secretion in control in Ins1CreZnT8KO mouse -cells.
To measure cytosolic free Zn2 levels, isolated islets were dispersed and infected with an
adenovirus expressing the Zn2-sensitive FRET probe eCALWY4 (34) (A). Steady-state
fluorescence intensity ratio (citrine to cerulean) was first measured 1) before obtaining the Rmax,
2) under perifusion with Krebs-Henseleit Buffer buffer containing the zinc chelator N,N,N
,N
-
Tetrakis(2-pyridylmethyl)ethylenediamine (50M; zinc-free condition). Finally, 3) the Rmin was
obtained under perfusion with Krebs-Henseleit Buffer buffer containing 5M pyrithione and
100M Zn2 (zinc-saturated condition), providing saturating intracellular Zn2 concentrations
(B). The free cytosolic concentration of Zn2 (C) was calculated using the next formula: [Zn2] 
Kd (Rmax  R)/(R  Rmin), revealing significant decreases in cytosolic free zinc levels in Ins1Cre:
ZnT8fl/fl animals compared with littermate controls (**, P  .01, Cre vs Cre, respectively, n 
20 Cre and n  11 Cre islets). Zinc secretion from isolated islets, using the zinc binding probe
zinc indicator for monitoring induced exocytotic release (ZIMIR), was decreased in Cre islets as
shown by significant decreases in both the amplitude (****, P  .0001, Student’s t test) and
AUC (*, P  .05, Student’s t test) of glucose-evoked ZIMIR responses; n  22 Cre islets and
n  17 Cre islets (D).
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Figure 5. Ins1CreZnT8KO mice exhibit abnormal granule morphology but unchanged -cell mass. Transmission electron microscopic images of
-cells from islets isolated from Cre (upper) or Cre (lower) animals show altered dense core granule structure. Scale bar, 1 m. A, Insulin
granules were grouped into 3 categories according to morphological structure and counted. Cre animals showed a significant reduction in
granules containing a dense core coupled with significant increases in granules showing a rod like structure or a gray interior (***, P  .001 vs
Cre) (B). No changes in total granule number were seen between genotypes (ns vs Cre) (C). Granule diameter was increased in Cre -cells
(****, P  .0001 vs Cre, Student’s t test) (D). Staining pancreatic slices from Cre (E, left) and Cre (E, right) (scale bar, 50 m) for insulin and
glucagon revealed no significant differences in - to -cell ratio (F), -cell mass (G), or -cell mass (H) (n  3 animals per genotype). Values
represent mean 	 SEM.
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ysis (Supplemental Figure 4). Treatment with doxycycline
of transgenic animals derived from founder 31 (5 copies)
resulted in an approximately 4-fold induction of human
ZnT8 mRNA expression (4.40 	 0.08 vs 16.9 	 0.40;
ZnT8 Tg vs ZnT8 Tg; P .0001; Student’s t test; n
3 per genotype) (Figure 6B). This
was accompanied by both an in-
crease in luciferase mRNA expres-
sion (4.78 	 0.06 vs 11.7 	 0.25;
ZnT8 Tg vs ZnT8 Tg; P .0001;
Student’s t test; n 3 each genotype)
(Figure 6C) and activity in isolated
islets (68.33	 2.85 vs 1362	 86.9;
ZnT8 Tg vs ZnT8 Tg; P .0001;
Student’s t test; n 3 each genotype)
(Figure 6D). The expression of hu-
man ZnT8 protein was also appar-
ent by Western blotting using an an-
tibody specific for the human
protein (Figure 6E).
Females from founder 31 dis-
played significant improvements in
glucose tolerance at both 10 weeks of
age (12.2 	 0.51 vs 13.9 	 1.1
mmol/L; ZnT8 Tg vs ZnT8 Tg;
P  .05, 15-min time point; repeated
measures two-way ANOVA; n  6
and 7, respectively) (Figure 7A) and
14 weeks of age (8.84 	 0.59 vs
11.7 	 1.01 mmol/L; ZnT8 Tg vs
ZnT8 Tg; P  .001, 30-min time
point, repeated measures two-way
ANOVA; *, P .05, AUC, Student’s
t test, n  8 and 5, respectively) (Fig-
ure 7B),whereas changeswere not ap-
parent in males (Supplemental Figure
5). Insulin sensitivity was unchanged
in 10-week-old female ZnT8 trans-
gene positive animals compared with
wild-type littermates (ns; repeated
measures two-way ANOVA; n  4
ZnT8 Tg and 5 ZnT8 Tg) (Figure
7C). Measured in vivo after ip injec-
tion of 3-g/kg glucose, insulin secre-
tion was significantly enhanced by al-
most 2-fold compared with wild-type
littermates, despite a tendency to-
wards lowered blood glucose levels
(*, P  .05; 15- and 30-min time
point; repeated measures two-way
ANOVA; n 6 ZnT8 Tg and n 8
ZnT8 Tg animals) (Figure 7D).
Both male and female mice derived from founder 23
(copy number 13) displayed no apparent changes in glu-
cose tolerance at either 10 or 14 weeks of age (Supple-
mental Figure 6, A–D), consistent with the significantly
lower levels of overexpression of the transgene and coex-
Figure 6. Selective overexpression of ZnT8 in the mouse -cell. Mice expressing human ZnT8
(hZnT8) and luciferase under the control of a bidirectional, tetracycline-regulated promoter were
crossed with RIP7-rtTA mice (28) and bred to give ZnT8 Tg mice (Rip7-rtTAZnT8Tg) and
littermate control animals (Rip7-rtTAZnT8). Administration of doxycycline in the drinking water
was used to induce ZnT8 overexpression specifically in the -cell (A). Quantitative PCR (qPCR)
revealed increased hZnT8 (****, P  .0001 vs ZnT8 Tg, n  3 animals per genotype) (B) and
luciferase (****, P  .0001 vs ZnT8 Tg, n  3 animals per genotype) (C) gene expression in
isolated mouse islets. Luciferase activity was also increased in islets isolated from ZnT8 Tg
animals (***, P  .001 vs ZnT8 Tg, n  4) (D). Western (immuno)blotting demonstrated
increased hZnT8 protein expression in isolated islets from transgenic mice (E).Values represent
mean 	 SEM.
84 Mitchell et al Impact of ZnT8 Modulation on Glucose Homeostasis Mol Endocrinol, January 2016, 30(1):77–91
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 11 January 2016. at 08:52 For personal use only. No other uses without permission. . All rights reserved.
pressed reporter gene (luciferase) in this line vs line 31
(Supplemental Figure 4).
ZnT8 Tg islets secrete less insulin but more Zn2
in response to glucose
Assayed in vitro, insulin secretion from isolated islets
derived from 10- to 14-week-old female mice in response
to high glucose (16.7mM) was significantly reduced
(0.94 	 0.21 vs 0.40 	 0.05 ng/mL, ZnT8 Tg vs ZnT8
Tg, respectively; P .05; two-way ANOVA, n 10–13
replicates) (Figure 8A). No differences were apparent in
the response of transgenic islets to stimulation with incre-
tin or depolarization with KCl (Figure 8A).
Demonstrating enhanced glucose-stimulated Zn2 se-
cretion from transgenic mouse islets, both the amplitude
(0.053	 0.002 vs 0.791	 0.05; ZnT8Tg vs ZnT8Tg,
respectively; P  .001; two-way
ANOVA, n  11 and 14, respec-
tively) and AUC (496 	 1.72 vs
505 	 2.11; ZnT8 Tg vs ZnT8
Tg, respectively; P  .01; n  11
and 14, respectively) of glucose-
evoked ZIMIR responses (Figure
8B) were increased by ZnT8 overex-
pression. Interestingly, there were
no changes in cytosolic Zn2 con-
centrations (1079 	 176pM vs
1020	 127pM; ZnT8 Tg vs ZnT8
Tg; ns; Student’s t test; n 46 and
61 cells, respectively, from 2–6 ani-
mals per genotype) (Figure 8C).
Staining pancreatic slices for in-
sulin and glucagon (Figure 8D) re-
vealed no changes in - or -cell
mass nor the ratio of - to -cells
(Figure 8, E–G).
Discussion
In this report, we describe new
mouse models for ZnT8, which pro-
vide insights into the pathogenic
mechanisms likely to be involved in
the actions of human alleles associ-
ated with increased T2D risk.
Ins1CreZnT8KO mice showed
dramatic changes in secretory gran-
ule morphology and plasma insulin
level under glucose stimulation, sim-
ilar to findings previously reported
in global ZnT8 KO mice (14), in
mice with conditional ZnT8 alleles
deleted with the more promiscuous RIP2Cre (15), or with
MIPCre which also expresses GH (24). The present re-
sults thus confirm that such morphological changes are
likely to be a -cell-autonomous event and to reflect im-
paired Zn2 uptake into dense core granules in the ab-
sence of ZnT8.
Despite the exaggerated glucose excursions and
smaller plasma insulin increases observed in response to
ip injection of the sugar in these animals (Figure 2, B and
E, respectively), islets derived from Ins1CreZnT8KO
mice displayed unaltered glucose-stimulated insulin se-
cretion in vitro. By contrast, glucose-induced Zn2 re-
lease from these islets was reduced by more than 80%, in
line with earlier results with global ZnT8 KO mice (36),
presumably reflecting impaired Zn2 accumulation by
Figure 7. Female ZnT8 Tg mice show improvements in glucose tolerance. Glucose tolerance
of Rip7-rtTAZnT8Tg animals was assessed by ip glucose tolerance test (IPGTT). A significant
improvement in glucose tolerance was seen in 10-week-old (*, P  .05, 15-min time point) (A)
and 14-week-old (**, P  .01, 30-min time point; *, P  .05 AUC) (B) female animals. Insulin
sensitivity was unchanged by ZnT8 overexpression (C). Plasma glucose (D, left) tended to be
reduced in ZnT8 Tg mice, but insulin (D, right) levels were significantly increased in response to
a 3-g/kg bodyweight ip injection of glucose (*, P  .05, 15- and 30-min time points). Values
represent mean 	 SEM.
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secretory granules. These findings reinforce the recent
proposal (19, 34) that impaired -cell Zn2 secretion and
deinhibition of insulin receptor endocytosis leads to ex-
aggerated clearance of mature insulin by the liver.
We extend support for the above view by showing that
glucose tolerance is improved in a new model in which
ZnT8 is selectively overexpressed in the -cell. Remark-
ably, insulin secretion from islets isolated from these mice
was barely stimulated by glucose, whereas Zn2 release
was increased by more than 50%. Nonetheless, fasting
insulin levels tended to be increased in ZnT8Tg animals
(Figure 7D), and these levels were further strongly in-
creased by ip glucose injection (Figure 7D). Thus, in
ZnT8Tg animals, elevated Zn2 secretion may act both
to impair insulin clearance through the internalization of
insulin receptors (19), and possibly
also to enhance insulin signaling.
At the molecular level, possible ac-
tions of the released Zn2 included
inhibition of insulin receptor de-
phosphorylation by protein ty-
rosine phosphatase B1 (38), or of
phosphatidylinositol (3,4,5) phos-
phate degradation by phosphatase
and tensin homologue on chromo-
some 10 (39).
These studies show that, by ma-
nipulating Slc30a8 expression selec-
tively in the mouse -cell using
molecular genetics, a near-linear re-
lationship exists in this species be-
tween ZnT8 levels and glucose tol-
erance (Figure 9A). Note that the
study of mice deleted for just one
conditional Slc30a8 allele was not
feasible with the breeding strategy
used here though, in earlier studies
with global Slc30a8 null mice (14),
we noted that heterozygous
(ZnT8/) mice displayed interme-
diate glucose tolerance between
wild-type and homozygous null an-
imals, consistent with the current
findings. Importantly, the changes
in peak glucose observed in the
present study were best correlated
to Zn2 release from the islet (Fig-
ure 9B): this was essentially elimi-
nated by Slc308 deletion (Figure
4D) but enhanced when the trans-
porter was overexpressed (Figure
8B). By contrast, insulin release in
vitro was inversely correlated with ZnT8 expression
(Figure 8C).
Interestingly, we observed differences between the im-
pact of Slc308 deletion on male and female mice, with
only males showing defective glucose tolerance over the
age range examined. In contrast, both male and female
mice deleted globally for the transporter (14) displayed
glucose intolerance at 6 weeks of age, whereas only males
were intolerant at 12 weeks. The reasons for the differ-
ences between the impact of Slc308 deletion between
sexes is presently unknown but may in part reflect the
intrinsically greater intermeasurement variability in fe-
males resulting from the reproductive cycle, and/or the
lower insulin sensitivity of male animals, which imposes a
greater metabolic stress on the -cell. Surprisingly, this
Figure 8. Insulin secretion and endocrine cell mass in ZnT8 Tg islets. Glucose-stimulated
insulin secretion was significantly reduced in isolated islets (*, P  .05) (A), whereas Zn2
secretion was enhanced as shown by significant increases in both the amplitude (***, P  .001)
(B, top) and AUC (**, P  .01) (B, bottom) of glucose-stimulated ZIMIR responses. Cytosolic Zn2
concentrations, measured using eCALWY4 (Figure 4), were unchanged by ZnT8 overexpression
(C). Staining pancreatic slices for insulin and glucagon (scale bar, 50 m) (D) revealed no changes
in -cell (E) or -cell (F) mass nor in - to -cell ratio (G). Values represent mean 	 SEM.
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position was reversed in transgenic animals with the
greater penetrance of ZnT8 overexpression observed in
females. In this case, the underlying mechanisms are less
clear but might reflect sex-specific differences in the han-
dling of enhanced Zn2 loads by the liver or other target
tissues (19).
Whether control of hepatic insulin clearance and/or ac-
tion via Zn2 assumes the same importance in man, where
themuch larger diameter and volume of the portal veinmay
mean greater dilution of Zn2 after release from the -cell,
and hence lowered action on the liver, is unclear. Nonethe-
less, and arguing for this possibility, carriers of risk (R)
SLC30A8 alleles show lowered C-peptide:insulin levels,
consistent with the more efficient uptake of the latter by
hepatocytes when Zn2 levels are lowered (40).
The present approach further
demonstrates the feasibility of using
mouse genetics to explore the mech-
anisms through which T2D risk
genes, identified in GWAS studies
(12), act. Intriguingly, we provide
additional evidence that the actions
of SLC30A8 involve interactions be-
tween multiple tissues (-cells and
liver), despite the tight restriction of
the expression of this gene to the en-
docrine pancreas (13). Whether
SLC30A8 variants also influence the
release of glucagon may require fur-
ther investigation; global inactiva-
tion of the gene exerted little effect
on glucagon release from islets, al-
though detailed in vivo analysis in-
volving hypoglycemic clamps were
not reported in these studies (15).
Fadista et al (41) recently reported a
strong positive correlation between
glucagon and SLC30A8 expression
in human islets, consistent with a
role for SLC30A8 variants in con-
trolling glucagon production.
In the light of the present results,
the possibility that otherGWAS genes
expressed in multiple tissues, eg,
TCF7L2 (42, 43), might act via extra-
pancreatic sites to regulate insulin se-
cretion,would seemworthy of careful
investigation. Of note, TCF7L2 is an
upstream regulator of the mouse
Slc30a8 (44) and human SLC30A
(45) genes and, as a “master” regula-
tor of T2D susceptibility (45), might
act in part via ZnT8 to modify -cell Zn2 release and in-
sulin clearance.
Materials and Methods
Ethical approval
All animal procedures were approved by the home office
according to the Animals (Scientific Procedures) Act 1986 of the
United Kingdom (PPL 70/7349).
Generation of -cell-selective knockout mice by
Ins1Cre-driven recombination
ZnT8 floxed mice (ZnT8fl/fl) were generated by GenOway
(15). This involved the insertion of a LoxP site together with a
flippase recognition target flanked neomycin selection cassette
Figure 9. Impact of ZnT8 manipulation in pancreatic -cells on murine glucose homeostasis.
Although glucose tolerance (A) and Zn2 secretion (B) are both increased with increasing ZnT8
levels, glucose-stimulated insulin secretion is impaired (C). Data are taken from Figures 2–4, 7,
and 8. Schematic representation, deletion of ZnT8 specifically in pancreatic -cells leads to
impaired glucose tolerance and abnormal insulin granule morphology. Conversely,
overexpressing ZnT8 in the -cell causes improvements in glucose tolerance but reduced glucose-
stimulated insulin secretion (D).
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within intron 1 and a single distal LoxP site within the upstream
exon 1 containing the translational start codon. ZnT8fl/fl ani-
mals were then bred with the Ins1Cre deleter strain, to produce
50% -cell-specific knockout animals (Ins1Cre/ZnT8fl/fl)
and 50% littermate controls (Ins1 Cre/ZnT8fl/fl). Note that,
in contrast to RIP2Cre (24) andMIP2Cre (19), Ins1Cre mice do
not express a GH cassette, and the transgene alone does not
affect glucose tolerance (25, 29). Animals were maintained in a
pathogen-free facility under a 12-hour light, 12-hour dark cycle
with free access to water and food.
Generation of -cell-specific transgenic mice
Plasmid pCDNA3, containing the human ZnT8 (W325
form) coding sequence with the addition of a single COOH-
terminal c-Myc epitope tag (14), was digested with XhoI,
blunt-end filled, and further digested withNotI. The digested
hZnT8-Myc DNA fragment was gel purified and cloned into
plasmid pBI-L Tet (Clontech) between NotI and PvuII sites.
This generated a plasmid with a bidirectional tetracycline-
regulated promoter driving expression of both hZnT8-Myc
and firefly luciferase. The positive clone was further con-
firmed by DNA sequencing using a pBI-L internal primer
GAAAGAACAATCAAGGGTCC and a hZnT8 primer
ACACTAGCACGCCAGTCACC.
The expression cassette was excised from the plasmid back-
bone by AatII and AseI digestion and transferred by pronuclear
microinjection into C57Bl/6 mouse oocytes (MRC Clinical Sci-
ences Centre transgenic facility, Hammersmith Hospital, Impe-
rial College London). Successful integration was identified by
PCR screening of DNA extracted from ear biopsies by the Hot-
SHOT method (46) using 2 sets of primers: 1) hZnT8 gene
forward, CTGTCATCGAAGCCTCCCTC and reverse,
AAGGGCATGCACAAAAGCAG; and 2) Luciferase gene for-
ward, CATTAAAACCGGGAGGTAGATGA and reverse,
CATGGATTCTAAAACGGATTACCA. The relative transgene
copy number was determined by SYBR green quantitative PCR
method (Life Technology) using a set of luciferase gene primers:
forward, CAACTGCATAAGGCTATGAAGAGA and reverse,
ATTTGTATTCAGCCCATATCGTTT, and, as an internal
control, a set of mouse Cxcl12 gene primers: forward, GGAC-
GAGCTCCACTTAGACG and reverse, CAACATGTCCA-
GATC GAAATC. Two founders were crossed twice with
C57Bl/6 mice to generate the hZnT8-Luc strain. RIP7-rtTA
mice on a C57Bl/6 background (28), expressing the reverse tet-
racycline transactivator under the control of the rat insulin pro-
moter, were crossed with hZnT8-Luc mice to permit -cell-
specific, tetracycline-inducible expression of hZnT8-Myc and
luciferase. hZnT8-Luc mice were crossed with homozygous
RIP7-rtTA mice to produce littermates of 2 genotypes as fol-
lows: hZnT8-Luc/RIP7-rtTA (ZnT8 Tg) and hZnT8
Luc/RIP7-rtTA (ZnT8 Tg). All offspring were genotyped
for both the hZnT8 and RIP7-rtTA genes (47). Mice were
treated with 0.5-g/L doxycycline from 5 weeks of age.
Islet isolation
Mice were euthanized by cervical dislocation and pancreatic
islets isolated by collagenase digestion as preciously described
(48). Given the sex- and age-dependent differences between
mouse lines, islets used for ex vivo analysis were obtained from
mice of the appropriate sex and, importantly, at an age where an
in vivo phenotype was apparent ie, 10-week-old male
Ins1Cre/::ZnT8fl/fl mice and 10- to 14-week-old female
Rip7rTta/::ZnT8Tg/ mice.
Quantitative real-time PCR
Total islet RNA was extracted using TRIzol reagent (Invit-
rogen). After reverse transcription, relative expression was as-
sessed using SYBR Green (Invitrogen). Primers were designed
using PerlPrimer and gene expression was normalized to -actin
(Actb).
Immunofluorescence
Isolated islets were fixed overnight at 4°C in 4%paraformal-
dehyde (vol/vol) before the addition of primary antibodies
against murine ZnT8 (1:200, raised in rabbit; Mellitech) insulin
(1:200, raised in guinea pig; DAKO), and glucagon (1:1000
raised in mouse; Sigma-Aldrich). Detection was performed us-
ing goat antirabbit Alexa Fluor 488, goat antiguinea pig Alexa
Fluor 568, and goat antimouse Alexa Fluor 568 (1:500; all
Invitrogen). Islets were mounted on Superfrost slides (Fisher
Scientific) using Vectashield 4
,6-diamidino-2-phenylindole-
containing hardset mounting medium (Vector Laboratories).
Data capture was performed using a Zeiss LSM780 confocal
microscope equipped with GaAsP spectral detectors and a64/
1.4NA oil-immersion objective. The proportion of ZnT8-im-
munopositive - and -cells was quantified according to colo-
calization of ZnT8 with either insulin or glucagon, above a
background threshold (ie, twice the signal to noise ratio). In all
cases, uniform linear adjustments were applied to contrast/
brightness to improve image quality for presentation while pre-
serving the pixel dynamic range. Background fluorescence after
insulin staining is likely to correspond to autofluorescence and
was left uncorrected to preserve image integrity for compari-
sons. Likewise, stippled background fluorescence after glucagon
staining can be attributed to nonspecific staining apparent when
the ZnT8 antibody was used in the presence of the antiglucagon
antibody.
Histology and immunohistochemistry
Mouse pancreata were extracted and fixed in 10% neutral
balanced formalin (Sigma) at 4°C for 18 hours before dehydra-
tion and wax embedding and processing to obtain 5-m slices.
Sections were labeled with antiinsulin (1:200 dilution; second-
ary Alexa Fluor 488, 1:1000) and antiglucagon (1:100 dilution;
secondary Alexa Fluor 568, 1:500) and sealed using Vector
Shield Antifade Hard Set reagent (Vector Laboratories). -Cell
mass was determined as described (49). Data capture was per-
formed using a Zeiss AxioObserver and a 40/0.75NA objec-
tive. /-Cell mass was calculated using the threshold plugin for
ImageJ (NIH), as previously detailed (50).
Intraperitoneal glucose and insulin tolerance tests
Glucose (1-g/kg bodyweight) was injected into the abdomen
of mice that had been fasted overnight. Blood glucose measure-
ments were taken at 0, 15, 30, 60, 90, and 120 minutes using an
automatic glucometer (Accucheck). Insulin tolerance tests are
performed as per glucose tolerance test but animals were fasted
for 5 hours before 0.75-U insulin/kg bodyweight insulin
injection.
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Plasma insulin measurements
Mice fasted overnight were injected with glucose (3-g glu-
cose/kg bodyweight) and blood from the tail vein was collected
into heparin coated tubes (Sarstedt) at 0, 15, and 30 minutes.
Plasma was separated by centrifugation at 2000g for 10 min-
utes, 5 L of blood plasma were used to measure insulin levels
using an ultrasensitive mouse insulin ELISA kit (Crystal Chem).
Insulin secretion assay
Five sizematched islets were pre incubated for 1 hour at 37°C
in a Krebs-HEPES-bicarbonate (KHB) buffer (130mM NaCl,
3.6mM KCl, 1.5mM CaCl2, 0.5mM MgSO4, 0.5mM
NaH2PO4, 2mM NaHCO3, 10mM HEPES, and 0.1% [wt/vol]
BSA; pH 7.4) containing 3 mmol/L glucose with gentle shaking
(120 rpm). Islets were further incubated for 30 minutes at 37°C
in either: 3 mmol/L glucose, 8 mmol/L glucose, 16.7 mmol/L
glucose, 16.7 mmol/L glucose plus 20 nmol/L GLP1, or 3
mmol/L glucose plus 30 mmol/L KCl, before collection of su-
pernatant fractions for insulin secretion analysis. Total insulin
was collected by lysing islets in 500 L acidified ethanol solu-
tion (1.5% [vol/vol] HCl, 75% [vol/vol] ethanol, and 0.1%
[vol/vol] Triton X-100) followed by sonication. Secreted and
total insulin was measured using Homogenous Time-Resolved
Fluorescence assay kit (Cisbio). Insulin release during perifusion
was monitored using a custom-built device. Experiments were
performed in triplicate and 50 islets were perifused at a rate of
500 L min1 at 37°C.
[Ca2]i imaging and connectivity analysis
Isolated islets were incubated (37°C, 95%O2/5%CO2) for 1
hour in fluo 2-AM (10M; Teflabs) diluted in a HEPES-bicar-
bonate buffer solution (120mM NaCl, 4.8mM KCl, 1.25mM
NaH2PO4, 24mM NaHCO3, 2.5mM CaCl2, 1.2mM MgCl2,
10mM HEPES, and 3mM D-glucose; all Sigma). Functional
multicellular Ca2 imaging was achieved using a Nipkow spin-
ning disk head allowing rapid scanning of islet areas for long
periods of time with minimal phototoxicity. A solid-state laser
(CrystaLaser) controlled by a laser-merge module (Spectral Ap-
plied Physics) provided wavelengths of 491 nm to excite fluo-2
(rate, 0.5 Hz; exposure time, 600 ms). Emitted light was filtered
at 525/50 nm, and images were captured by a highly sensitive
16-bit, 512  512 pixel back-illuminated EM-CCD camera
(ImageEM 9100–13; Hamamatsu). Volocity software
(PerkinElmer) provided the user interface. During recordings,
islets were maintained at 35°C–36°C and continuously irrigated
with bicarbonate buffer aerated with 95% O2/5% CO2. Con-
nectivity analysis was performed as previously described (31).
ZIMIR imaging
ZIMIR imaging was performed as previously described (36).
Briefly, isolated islets were incubated (37°C, 95%O2/5% CO2)
in ZIMIR (1M) for 30 minutes and imaged in bicarbonate
buffer solution supplemented with 1M EDTA to improve the
signal to noise ratio. ZIMIR was excited at 491 nm and emitted
signals captured at 525 nm.After acquisition, islets were divided
into subregions before extraction of intensity over time to allow
analysis of amplitude and AUC of glucose-stimulated ZIMIR
responses.
Cytosolic free Zn2 measurements
Zn2 measurements were acquired as previously described
(31). Briefly, islets were dispersed onto coverslips before infec-
tion with adenovirus containing the FRET-based Zn2 sensor
eCALWY4. Steady-state fluorescence intensity ratio citrine to
cerulean (R) was measured, then maximum ratio (Rmax) and
minimum ratio (Rmin) were determined to calculate free Zn2
concentration using the next formula: [Zn2]  Kd (Rmax 
R)/(RRmin). The Rmax was obtained upon intracellular zinc
chelation with 50M N,N,N
,N
-Tetrakis(2-pyridylmethyl)
ethylenediamine and the Rmin was obtain upon Zn2 satura-
tion with 100MZnCl2 in the presence of the Zn2 ionophore,
pyrithione (5M).
Protein extraction and Western (immuno)blotting
analysis
For protein analysis, roughly 100 islets were washed twice in
ice-cold PBS and lysed in ice-cold radioimmunoprecipitation
assay buffer (50mM Tris HCl [pH 8.0], 150mM NaCl, 1%
nonylphenoxypolyethoxylethanol, 0.5% sodium deoxycholate,
and 0.1% sodium dodecyl sulfate). Protein was assayed with a
BCAkit (Pierce). Total protein extracts (30g) were resolved by
sodium dodecyl sulfate-PAGE (8% vol/vol acrylamide) and
transferred to polyvinylidene fluoride membranes, followed by
immunoblotting with either rabbit polyclonal antimouse or an-
tihuman ZnT8 (both 1:200, Millitech clone R/PZ8) and mouse
monoclonal antitubulin (1:5000, Sigma clone B-5–1-2) antibod-
ies. Secondary horse radish peroxidase-linked antirabbit or an-
timouse antibodies (1:3000; GE Healthcare) were revealed by
using enhanced chemiluminescence detection reagent (GE
Healthcare).
Transmission electron microscopy
Isolated islets were fixed in Vincenzo’s fixative (2% parafor-
maldehyde, 2.5% glutaraldehyde, 3mM CaCl2, and 0.1M so-
dium cacodylate buffer [pH 7.4]) for 20 minutes at 37°C ini-
tially followed by a further 2 hours at room temperature and
finally overnight at 4°C. Electron microscopy was performed as
previously described (51).
Statistical analysis
Values represented are the mean 	 SEM. Statistical signifi-
cance was assessed using either Student’s t test or the Mann-
Whitney U test depending on data distributions. Two-way
ANOVA (with Bonferroni or Sidak multiple comparison test)
was used to examine the effect of multiple variables. Statistical
analyses were performed using GraphPad Prism 6.0, ImageJ,
and IgorPro.
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